Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients

ology, University Hospital, Uppsala. "In past randomized studies using either IL-2 alone or similar agents we have not seen evidence of significant benefit to the patients. The Maxamine results suggest the potential for a meaningful advancement in the care of AML patients."

Patients treated in their second or subsequent remission ("CR2+") historically have a poor prognosis with about 5% achieving long-term survival. The 13 CR2+ patients treated with Maxamine Therapy in the ongoing Phase II study have experienced a substantial increase in remission duration, highlighted by the following results updated as of September 1, 1998:

The median time to relapse for the CR2+ patients was 21 months, more than three times the six-month historic median.

Only 10-20% of AML patients under the current standard of care historically achieve remission inversions, the lengthening of subsequent remission times beyond the duration of their previous remissions. However, 8 of 11 (73%) of the evaluable CR2+ patients treated with Maxamine Therapy have achieved remission inversion.

Moreover, 38% of the CR2+ patients treated with Maxamine Therapy remain in leukemia-free remission.

Quality of Life during Maxamine Therapy

In the Phase II study, patients have administered more than 8,000 doses of Maxamine at home. No unexpected side effects from the drug have been identified during the study. The majority, 75%, of the evaluable patients have returned to work while taking Maxamine Therapy. The study results suggest that the administration of Maxamine Therapy at home as a remission therapy for AML is both safe and feasible.

"Quality of life is very important for AML patients during remission," said Dr. Brune. "The ability to provide remission therapy on an outpatient, at-home, basis is essential to allow the patients to maintain as closely as possible their normal lifestyle."

Maxamine Mechanism of Action

In many patients with chronic infectious

Contact: Amy Flood
415-677-4455 x211
Noonan/Russo Communications

Page: 1 2 3 4 5 6

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. Phase II trial of anthrax vaccine to begin
3. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
4. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
5. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
6. Penn researchers announce results of Phase I trial using combretastatin drug
7. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
8. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
11. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

Post Your Comments:

(Date:8/31/2018)... (PRWEB) , ... August 31, 2018 , ... ... its neuroimaging capabilities with the addition of an MRI Simulator. In the MRI ... scan including sounds. By engaging in this mock scan experience, research participants become ...
(Date:8/31/2018)... Calif. (PRWEB) , ... August 31, 2018 , ... Nitro ... at SeaLegs at the Beach – an action sports gathering to celebrate the life ... Crew. The event raised money for Erik’s wife, Annika and their two small children, ...
(Date:8/31/2018)... ... August 31, 2018 , ... Saturday, September 1st, 2018, Team Fastrax™ will perform ... Cyclones season opener game. At 7pm, the Cyclones will kick off against the South ... play, Team Fastrax™ will jump in with their majestic 2,000 sq. ft. American Flag, ...
(Date:8/29/2018)... PHILADELPHIA (PRWEB) , ... August 29, 2018 , ... ... Pennsylvania region announced that they will be relocating two of their offices ... location in Mechanicsburg, PA, just a few miles away, located on the campus of ...
(Date:8/29/2018)... ST. LOUIS, Mo. (PRWEB) , ... August 29, ... ... infographic entitled “Smoking vs. Vaping: What You Need to Know” to provide information ... infographic , The Vape Mall lays out the similarities, and, more importantly, differences ...
Breaking Medicine News(10 mins):
(Date:9/15/2018)... N.C. (PRWEB) , ... September 14, 2018 , ... "As ... on the map thanks to Hurricane Florence. I am planning this Women of Influence ... living out of a suitcase and knowing I have to hold onto my faith ...
(Date:9/13/2018)... ... September 13, 2018 , ... NCPDP announced today that ... ensure correct implementation of the NCPDP SCRIPT Standard Version 2017071 ahead of the ... transactions identified by the industry as vital enhancements in improving patient safety, clinical ...
(Date:9/12/2018)... ... September 12, 2018 , ... Surgical Theater will be exhibiting ... September 19-22. The IT + Revenue Cycle Conference provides Surgical Theater with a ... use of Precision Virtual Reality™ medical visualization platform. This 360VR technology allows patients ...
Breaking Medicine Technology:
Cached News: